# Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

> **NCT01032382** · PHASE2 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 30 (actual)

## Conditions studied

- Leishmaniasis, Cutaneous

## Interventions

- **DRUG:** WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
- **DRUG:** Paromomycin Alone Cream (15% paromomycin topical cream)

## Key facts

- **NCT ID:** NCT01032382
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-03
- **Final completion:** 2011-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01032382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01032382, "Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01032382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*